Sveriges Riksbank
Bid date, 2021-01-21 | |
Bid Date | 2021-01-21 |
Bid times | 14.00-14.30 (CET/CEST) on the Bid date |
Offerent Amount | USD 10 billion |
Maximum Permitted Volume of Bids | USD 4 billion from an individual institution |
Settlement Date | 2021-01-25 |
Minimum Permitted Bid Volume | 100 USD million per bid |
Maximum Allocation | 40 per cent of the Offerend amount |
Allocation time | Not later than 15.00 (CET/CEST) on the Bid date |
Maturity Date | 2021-04-19 |
Maximum Number of Bids | 10 per individual institution |
Lowest Interest Supplement | 0.25 percentage points |
Confirmation of bids to e-mail | eol@riksbank.se |
Stockholm, 2021-01-19
This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions can be retrieved at www.riksbank.se.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Biotalys NV18.9.2025 07:00:00 CEST | Press release
Biotalys Reports Half-Year 2025 Financial Results and Business Highlights
F. Hoffmann-La Roche Ltd18.9.2025 07:00:00 CEST | Press release
Roche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH
Ascom Holding AG18.9.2025 06:30:00 CEST | Press release
Michael Reitermann takes over the operational leadership of the Ascom Group as Delegate of the Board of Directors and interim CEO
Novo Nordisk A/S17.9.2025 23:05:02 CEST | Press release
Novo Nordisk’s oral semaglutide 25 mg (Wegovy® in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study
Biogen Inc.17.9.2025 22:30:05 CEST | Press release
Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom